Associate Professor, Medicine, University of Colorado School of Medicine

Oncology

Ross Camidge practices Oncology. He has 1 awards "CMS Meaningful Use Stage 1 Certification". Ross Camidge has written publications. He has 43 publications published with PubMed. The lastest publication is: 'Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.'

Publications

---

• NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.
• A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non-Small Cell Lung Cancer Clinical Trials: A Review of the Clinical...
• Alectinib in ALK-positive, crizotinib-resistant, non-small-cell Lung cancer: a single-group, multicentre, phase 2 trial.
• Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
• Buyer beware: understanding the assumptions behind health economic assessments in personalized Cancer care.
• Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Non-Small-Cell Lung Cancer.
• Crizotinib effects on creatinine and non-creatinine-based measures of glomerular filtration rate.
• Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metasta...
• Clinicopathologic features and outcomes of patients with Lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
• Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer.
• Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations.
• A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non-Small-Cell Lung Can...
• Acquired resistance to TKIs in solid tumours: learning from Lung cancer.
• A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic ...
• Using multiplexed assays of oncogenic drivers in Lung cancers to select targeted drugs.
• Downstaging of Non-Small-Cell Lung Cancer Through Identification of Reversible Drug Toxicity.
• FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity Across All Lung Cancer Histologies.
• Ceritinib in ALK-rearranged non-small-cell Lung cancer.
• Atypical Negative ALK Break-Apart FISH Harboring a Crizotinib-Responsive ALK Rearrangement in Non-Small-Cell Lung Cancer.
• A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cel...
• Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lun...
• Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combinati...
• Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell Lung cancer treated with the ALK inhibitor crizotinib.
• Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group.
• Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.
• Native and rearranged ALK copy number and rearranged cell count in non-small cell Lung cancer: Implications for ALK inhibitor therapy.
• Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kin...
• Icotinib: kick-starting the Chinese antiCancer drug industry.
• Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies-results of a phase I dose-escalation study.
• Crizotinib versus chemotherapy in advanced ALK-positive Lung cancer.
• Initial Clinical Sensitivity and Acquired Resistance to MET Inhibition in MET-Mutated Papillary Renal Cell Carcinoma.
• Symptomatic reduction in free testosterone levels secondary to crizotinib use in male Cancer patients.
• Taking Aim at ALK Across the Blood-Brain Barrier.
• Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer.
• Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an ...
• A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell Lung cancer.
• Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell Lung cancer.
• Activity and safety of crizotinib in patients with ALK-positive non-small-cell Lung cancer: updated results from a phase 1 study.
• Treating ALK-positive Lung cancer--early successes and future challenges.
• Targeted manipulation of apoptosis in Cancer treatment.
• Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer.
• Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell Lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.

Schools

---

• University Of Oxford Oxford Uk

• John Radcliffe Hospital Oxford Uk

• University Of Newcastle

• Edinburgh University

• Royal Postgraduate Medical School

• University Of Oxford

• PHD Molecular Biology Cambridge University

Conditions Treated

---

• Lung Cancer
• Pleura Cancer
• Pleural Neoplasm, Malignant
• Thymomas

Doctors Specialties

---

• Medical Oncology
• Oncology
• Thoracic Oncology

Accepted Insurances

---

• Aetna HMO
• Choice Plus POS II
• American Republic
• Pathway X Bronze Direct CACA IN HIX
• Anthem Blue Cross Blue Shield PPO
• Blue Card PPO
• Cigna HMO
• Cigna PPO
• Great West Healthcare-Cigna PPO
• LocalPlus
• Open Access Plus
• Coventry Health Care
• First Health (Coventry Health Care) PPO
• Golden Rule
• Medicare MCR
• MultiPlan PPO
• PHCS Network PPO
• MVP Health Care
• Choice Plus POS
• Navigate HMO
• Navigate POS
• Options PPO
• United Healthcare

Awards

---

• CMS Meaningful Use Stage 1 Certification

Hospital

---

• University of Colorado Hospital

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Han Myint, MD This Doctor is OpenDoctor Recommended.
	Dr. Eamon M. Berge, MD This Doctor is OpenDoctor Recommended.
	Dr. Anthony D. Elias, MD This Doctor is OpenDoctor Recommended.
	Dr. Robert C. Doebele, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Jonathan A. Gutman, MD This Doctor is OpenDoctor Recommended.
	Dr. L Michael Glode, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Vibha T. Thomas, MD This Doctor is OpenDoctor Recommended.
	Dr. Sami G. Diab, MD This Doctor is OpenDoctor Recommended.
	Dr. Jose I. Mayordomo, MD This Doctor is OpenDoctor Recommended.
	Dr. Wells A. Messersmith, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Michael S. Guy, MD This Doctor is OpenDoctor Recommended.
	Dr. Angela M. Davies, MD This Doctor is OpenDoctor Recommended. This doctor has more publications

---

Doctor Directory | TOS | twitter | FB | Angel | blog